

MarketVue®

Alport Syndrome

June 2022



MarketVue®: Alport Syndrome

UNDERSTAND THE ALPORT SYNDROME MARKET

MarketVue market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Methodology: Research is supported by 3 qualitative interviews with key opinion leaders (U.S. nephrologists), a quantitative survey with 25 U.S. physicians and secondary research.

Geographies covered: United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

TOPICS COVERED

EPIDEMIOLOGY: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

CURRENT TREATMENT: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

UNMET NEEDS: Identify opportunities to address treatment or disease management gaps

PIPELINE ANALYSIS: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

VALUE AND ACCESS: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



MarketVue®: Alport Syndrome

UNDERSTAND THE ALPORT SYNDROME MARKET

COMPANIES MENTIONED

- Reata Pharmaceuticals
- Sanofi
- Chinook Therapeutics
- River 3 Renal Corp
- Traverre Therapeutics

DRUGS MENTIONED

- Angiotensin-receptor blockers (ARBs)
- Spironolactone
- Eplerenone (Inspra)
- Dapagliflozin (Farxiga)
- Empagliflozin (Jardiance)
- Bardoxolone
- Lademirsen
- Atrasentan
- Lisinopril (Prinivil, Zestril)
- Sparsentan (Filspari)
- R3R01
- Ramipril (Altace)

MarketVue®: Alport Syndrome

Table of Contents

| | |
|--|----------------|
| 1. DISEASE OVERVIEW | 6 - 8 |
| A progressive, inherited nephropathy | 6 |
| Alport syndrome progresses in four phases | 6 |
| Figure 1.1. Phases of Alport syndrome disease progression | 6 |
| There are three types of Alport syndrome | 7 |
| Table 1.1. Types of Alport syndrome | 7 |
| Figure 1.2. Percent of XLAS patients that progress to ESRD by age and sex | 7 |
| Figure 1.3. Modes of inheritance for Alport syndrome | 7 |
| Hearing loss and eye abnormalities in Alport syndrome | 8 |
| Figure 1.4. Percentage of nephrologists who “often-to-always” coordinate patient care with other specialists | 8 |
| 2. EPIDEMIOLOGY & PATIENT POPULATIONS | 9 - 11 |
| Disease definition | 9 |
| Figure 2.1. G7 diagnosed prevalent cases of Alport syndrome by region | 9 |
| Table 2.1. Diagnosed prevalent and drug-treated patients in the U.S. and EU5 | 9 |
| Treatment rates are high although AS is underdiagnosed | 10 |
| Figure 2.2. Percentage of key patient subpopulations – mode of inheritance and gender | 10 |
| Patients have a significant influence over the evolving treatment landscape of AS | 11 |
| 3. CURRENT TREATMENT | 12 - 19 |
| Drug-treated patients and treatment rates | 12 |
| Table 3.1. Treatment initiation and rates by risk of disease progression | 12 |
| Figure 3.1. Percentage of nephrologists initiating treatment with ACEis/ARBs in Alport patients | 12 |
| Current standard of care is to achieve RAS blockade and blood pressure control with ACEis and ARBs | 13 |
| Standard of care – Blood pressure-lowering medicines | 13 |
| Figure 3.2. Current treatment share by patient subtype | 13 |
| Figure 3.3. Nephrologists’ opinion on deciding treatment between ACEis and ARBs | 13 |
| Nephrologists’ opinion on current treatments for Alport syndrome | 14 |
| Current treatment algorithm for Alport syndrome | 15 |
| Figure 3.4. Diagnosis and treatment flow for Alport syndrome | 15 |

MarketVue®: Alport Syndrome

Table of Contents

| | |
|--|----------------|
| Nephrologists' opinion on currently available treatments | 16 |
| Figure 3.5. Standard of care – upside and downside | 16 |
| Figure 3.6. Nephrologist-reported percentage of patients with unsatisfactory outcomes on current treatments | 16 |
| Almost all nephrologists see AS patients | 17 |
| Treating physicians and their patient load | 17 |
| Coordination of care for Alport syndrome | 17 |
| Figure 3.7. Percentage of nephrologists coordinating with other specialists | 17 |
| Disease awareness continues to be low, affecting timely treatment | 18 |
| Current and future must-know treatment dynamics | 18 |
| Figure 3.8. Percentage of nephrologists citing low disease awareness as a significant barrier to Alport syndrome diagnosis among GPs and other nephrologists | 18 |
| AS market likely to remain unchanged in the next few years | 19 |
| Figure 3.9. Potential Timeline of Alport Syndrome Market Evolution | 19 |
| 4 . UNMET NEED | 20 - 22 |
| Treatment-related unmet needs | 20 |
| Figure 4.1. Top Unmet Needs in Alport syndrome | 20 |
| Figure 4.2. Nephrologist ranking of unmet needs in Alport syndrome | 20 |
| Patients want a disease-targeting therapy that prevents progression to renal failure | 21 |
| Alport syndrome patients' insights on unmet needs | 21 |
| Figure 4.3. Percentage of patients experiencing various negative effects of Alport Syndrome on daily living | 21 |
| Low disease awareness among GPs is a significant diagnostic barrier for AS | 22 |
| Barriers to diagnosis | 22 |
| Figure 4.4. Percentage of nephrologists rating barrier as significant in timely diagnosis of Alport syndrome patients | 22 |
| 5 . PIPELINE ANALYSIS | 23 - 29 |
| Overview | 23 |
| Figure 5.1. Percentage of nephrologists with aided awareness of emerging therapies for Alport syndrome | 23 |
| Table 5.1. Emerging clinical-stage therapies for Alport syndrome and nephrologist awareness | 23 |
| Nephrologists see endothelin receptor antagonists as promising targets | 24 |

MarketVue®: Alport Syndrome

Table of Contents

| | |
|--|----------------|
| Figure 5.2 Percentage of U.S. nephrologists rating target as “promising” | 24 |
| Basket trials are becoming a more common way to study drugs targeting Alport syndrome | 25 |
| Comparison of ongoing trials in Alport syndrome | 26 |
| Table 5.2 Comparison of clinical stage Phase 2 or 3 studies in Alport syndrome | 26 |
| Bardoxolone Case Study: Overview and issues raised during FDA review | 27 |
| Regulatory review of bardoxolone | 27 |
| Figure 5.3. Key issues identified during FDA review of bardoxolone | 27 |
| Bardoxolone Case Study (Cont): KOL perspective on clinical issues identified during FDA review | 28 |
| Bardoxolone Case Study (Cont): Broader implications and patient reactions | 29 |
| 6 . VALUE & ACCESS | 30 - 31 |
| Overview | 30 |
| Value & Access Analogue: An Innovative Approach in Acute Hepatic Porphyria | 30 |
| Figure 6.1. Prevalence-based adjustments | 30 |
| Value & Access Analogue: A Traditional Approach in Sickle Cell Disease | 31 |
| 7 . METHODOLOGY | 32 - 33 |
| Primary Market Research Methodology | 32 |
| Epidemiology Methodology | 33 |
| Disease Definition | 33 |
| Diagnosed Prevalence Estimates | 33 |
| Drug-treatment rates | 33 |

Meet the REACH Team



DANIELLE DRAYTON, PhD., Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



MELISSA CURRAN is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



MICHAEL HUGHES, MSc, Ph.D., Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

Meet the REACH Team



TYLER JAKAB, MPH is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



BAYLEY KOOPMAN is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



BRIANA MULLINS is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.